Christopher Barbieri

Christopher Barbieri
About Christopher Barbieri

Dr. Christopher Barbieri, under the mentorship of Dr. Mark Rubin has identified a unique subclass of prostate cancer. Recurrent mutations in the gene for SPOP define this unique subset of patients. SPOP mutations result in the loss of the critical functions leading to increased invasiveness of the tumor which facilitates metastatic spread. Dr. Barbieri’s research will further inform subtyping of prostate cancer patients. This classification, in time, will support personalized treatment for patients. Discovery of SPOP inhibitors holds potential for a new therapy for metastatic prostate cancer.


The 2011 Peter and Laurie Grauer – PCF Young Investigator Award

Christopher Barbieri, MD, PhD

Weill Cornell Medical College


Mark Rubin, MD